Now showing items 1-5 of 5

    • Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. 

      Webster, Lucy; Groskreutz, Derek; Grinbergs-Saull, Anna; Howard, Rob; O'Brien, John Tiernan; Mountain, Gail; Banerjee, Sube et al. (2017-05)
      BACKGROUND: There is currently no disease-modifying treatment available to halt or delay the progression of the disease pathology in dementia. An agreed core set of the best-available and most appropriate outcomes for ...
    • DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT 

      Jones, Rob; Sheehan, Bart; Phillips, Patrick; Juszczak, Ed; Adams, Jessica; Baldwin, Ashley; Ballard, Clive et al. (2009-07-24)
      Abstract Background Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while ...
    • The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease. 

      Ritchie, Craig W; Russ, Tom C; Banerjee, Sube; Barber, Bob; Boaden, Andrew; Fox, Nick C; Holmes, Clive et al. (Springer Nature, 2017-10-26)
      Context: This article discusses the implications of disease-modifying treatments for Alzheimer’s disease which seem likely to appear in the next few years and results from a meeting of British experts in neurodegenerative ...
    • Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. 

      Sims, Rebecca; van der Lee, Sven J; Naj, Adam C; Bellenguez, Céline; Badarinarayan, Nandini; Jakobsdottir, Johanna; Kunkle, Brian W et al. (2017-09)
      We identified rare coding variants associated with Alzheimer's disease in a three-stage case-control study of 85,133 subjects. In stage 1, we genotyped 34,174 samples using a whole-exome microarray. In stage 2, we tested ...
    • The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease 

      Ritchie, Craig W; Russ, Tom C; Banerjee, Sube; Barber, Bob; Boaden, Andrew; Fox, Nick C; Holmes, Clive et al. (2017-10-26)
      Abstract Context This commentary discusses the implications of disease-modifying treatments for Alzheimer’s disease which seem likely to appear in the next few years and results ...